AIRR - ANZCA Institutional Research Repository
Skip navigation
Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorde Looze Fen_US
dc.contributor.authorRusso Men_US
dc.contributor.authorBloch Men_US
dc.contributor.authorMontgomery Ben_US
dc.contributor.authorShephard Aen_US
dc.contributor.authorSmith Gen_US
dc.contributor.authorAspley Sen_US
dc.description.abstractBACKGROUND: Viral infections cause most cases of pharyngitis (sore throat); consequently, antibiotics are generally not warranted. However, a treatment targeting pain and inflammation, e.g. a topical non-steroidal anti-inflammatory spray, may be helpful for patients. OBJECTIVE: To evaluate the efficacy and safety of flurbiprofen 8.75 mg spray. METHODS: This randomised, double-blind, parallel group study was conducted at six community-based clinical research centres in Australia and two in New Zealand. Adults with sore throat due to upper respiratory tract infection (onset ≤ four days) took one dose of flurbiprofen (n = 249) or placebo spray (n = 256); after six hours, they could re-dose every three-six hours as required, for three days (max. five doses/day). The primary endpoint was the area under the change from baseline curve in throat soreness from zero-two hours (AUC0-2h). The change from baseline in other sore throat symptoms also assessed efficacy. RESULTS: The mean AUC0-2h for throat soreness was significantly greater with flurbiprofen spray (-1.82; 95% CI: -1.98 to 1.65) compared with placebo (-1.13; 95% CI: -1.27 to 0.99) (P < 0.0001). Significantly greater reductions from baseline were observed with flurbiprofen spray compared with placebo from the first time-points assessed (five minutes for throat soreness/difficulty swallowing, 20 minutes for sore throat pain intensity and 30 minutes for swollen throat) for up to six hours (P < 0.05 for all). There was no significant difference in adverse events between treatment groups during the three-day study. CONCLUSION: Flurbiprofen spray provides rapid and long-lasting relief from sore throat symptoms, and is well-tolerated over three days.en_US
dc.subjectnon-steroidal anti-inflammatoryen_US
dc.subjectrespiratory tract infectionen_US
dc.subjectsore throaten_US
dc.titleEfficacy of flurbiprofen 8.75 mg spray in patients with sore throat due to an upper respiratory tract infection: A randomised controlled trialen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleEuropean Journal of General Practiceen_US
dc.description.affiliatesAusTrials Pty Ltd, Sherwood, QLD, Australia and School of Medicine , University of Queensland , Brisbane , QLD , Australiaen_US
dc.description.affiliatesHunter Clinical Research , Broadmeadow , Newcastle , NSW , Australiaen_US
dc.description.affiliatesHoldsworth House Medical Practice , Darlinghurst , NSW , Australiaen_US
dc.description.affiliatesOptimal Clinical Trials , Auckland , New Zealanen_US
dc.description.affiliatesReckitt Benckiser Healthcare International Ltd. , Slough , Berkshire , UKen_US
dc.type.studyortrialRandomized Controlled Clinical Trial/Controlled Clinical Trialen_US
item.openairetypeJournal Article-
item.fulltextWith Fulltext-
Appears in Collections:Scholarly and Clinical
Show simple item record

Page view(s)

checked on Sep 29, 2023

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.